Perfusion

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daniel, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Daniel, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Perfusion, Vol. 11, No. 3, 246-255 (1996)
DOI: 10.1177/026765919601100310

Reviews

Review on the multifactorial aspects of bioincompatibility in CPB

Serge Daniel

COBE Cardiovascular, Rungis, France

'In cardiopulmonary bypass as applied to open heart surgery, we are no longer looking for improving one thing 100% but improving everything by 1 %.'

Adapted from Mr Carlson, CEO, Scandinavian Airlines.

Over the last few years, a great emphasis has been placed on the bioincompatibility of foreign, nonphysiological materials used during CPB. It is only recently that bioincompatibility has objectively been recognized to be multifactorial, with the dominant implicated sources being cardiotomy blood suction, shear stresses or flow dynamics and, to a lesser degree, the blood/artificial surface interactions, the heparin/protamine complex and the various forms of emboli or debris.

In summary, in CPB, the reduction of postoperative complications, such as whole body inflammatory reactions, bleeding and organ dysfunctions, can only be impacted if the primary, dominant sources of bioincompatibility are reduced or eliminated.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
U. Abdel-Rahman, F. Ozaslan, P. S. Risteski, S. Martens, A. Moritz, A. Al Daraghmeh, H. Keller, and G. Wimmer-Greinecker
Initial Experience With a Minimized Extracorporeal Bypass System: Is There a Clinical Benefit?
Ann. Thorac. Surg., July 1, 2005; 80(1): 238 - 243.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
G. Wimmer-Greinecker, G. Matheis, S. Martens, G. Oremek, U. Abdel-Rahman, and A. Moritz
Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences
Eur. J. Cardiothorac. Surg., August 1, 1999; 16(2): 211 - 217.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
C B. Mahoney
Heparin-bonded circuits: clinical outcomes and costs
Perfusion, May 1, 1998; 13(3): 192 - 204.
[Abstract] [PDF]